Elevated cholesterol is one of the most well-documented and most controllable modifiable cardiovascular risk factors: decades of epidemiological studies, Mendelian randomization studies, and clinical trials with statins have established that LDL cholesterol is… Read more.
43 factors with evidence, ordered from highest to lowest effectiveness. Information, not medical advice.
⏱ 3 min read
Elevated cholesterol is one of the most well-documented and most controllable modifiable cardiovascular risk factors: decades of epidemiological studies, Mendelian genetic studies, and clinical trials with statins have established that LDL cholesterol is a robust causal factor for atherosclerosis and cardiovascular events when it remains elevated for years; the good news is that there are nutritional and pharmacological interventions with clearly significant effect sizes that reduce risk in proportion to the magnitude and duration of the reduction.
Mediterranean pattern (with EVOO —extra virgin olive oil— as the main fat, oily fish, nuts, legumes, vegetables, fruit, whole grains): reduces cardiovascular events by 30% according to PREDIMED.
Reducing saturated fat from processed meats and ultra-processed foods (not the saturated fat in whole food matrices such as yogurt or aged cheese).
Increased soluble fiber: - Oat beta-glucans (3-4 g/day): 5-10% LDL reduction. - Psyllium (10-15 g/day): 6-15% LDL reduction.
Phytosterols (2-3 g/day): 8-15% LDL reduction. Available in fortified foods or supplements.
Nuts (30 g/day): modest reduction in LDL and cardiovascular events.
Soy and plant protein: modest reduction.
Red yeast rice (with monacolin K): the most potent among the supplements. LDL reductions of 15-25% with doses of 10 mg/day of monacolin K. Important: the same molecule as lovastatin (a pharmaceutical statin), with the same precautions (interactions, myopathy, rare hepatotoxicity); do not combine with statins.
Berberine (500 mg 2-3 times/day): modest LDL reduction and improvement of the glycemic profile, synergistic with low-dose statins.
Citrus bergamot (500-1000 mg/day): modest reduction.
Omega-3 EPA/DHA (2-4 g/day): especially effective for triglycerides (20-30% reduction); modest effect on LDL.
Aged garlic: modest reduction.
Niacin: potent for HDL and triglycerides, but modern trials (AIM-HIGH, HPS2-THRIVE) show no added reduction in events on top of statins; limited use.
In people with: - Established cardiovascular disease. - Diabetes with elevated cardiovascular risk. - LDL > 190 mg/dL (suspected familial hypercholesterolemia). - SCORE cardiovascular risk > 10%.
Statins are first-line treatment because of their robust evidence of reducing cardiovascular and all-cause mortality. Significant adverse effects (clinically important myopathy, hepatotoxicity, new-onset diabetes in predisposed people) are less frequent than popular culture suggests; most patients tolerate statins well.
For moderately elevated cholesterol in people at low risk, nutritional interventions (Mediterranean diet + soluble fiber + phytosterols + nuts) may be sufficient. For markedly elevated cholesterol or significant cardiovascular risk, the combination of nutritional interventions plus statins or a pharmacological equivalent is the best-supported strategy. Red yeast rice is an interesting intermediate alternative with real pharmacological properties from monacolin K, but it should be treated with the same clinical respect as statins.
⏱ 3 min read
Elevated cholesterol is one of the most well-documented and most controllable modifiable cardiovascular risk factors: decades of epidemiological studies, Mendelian genetic studies, and clinical trials with statins have established that LDL cholesterol is a robust causal factor for atherosclerosis and cardiovascular events when it remains elevated for years; the good news is that there are nutritional and pharmacological interventions with clearly significant effect sizes that reduce risk in proportion to the magnitude and duration of the reduction.
Mediterranean pattern (with EVOO as the main fat, oily fish, nuts, legumes, vegetables, fruit, whole grains): reduces cardiovascular events by 30% according to PREDIMED.
Reducing saturated fat from processed meats and ultra-processed foods (not the saturated fat in whole food matrices such as yogurt or aged cheese).
Increased soluble fiber: - Oat beta-glucans (3-4 g/day): 5-10% LDL reduction. - Psyllium (10-15 g/day): 6-15% LDL reduction.
Phytosterols (2-3 g/day): 8-15% LDL reduction. Available in fortified foods or supplements.
Nuts (30 g/day): modest reduction in LDL and cardiovascular events.
Soy and plant protein: modest reduction.
Red yeast rice (with monacolin K): the most potent among the supplements. LDL reductions of 15-25% with doses of 10 mg/day of monacolin K. Important: the same molecule as lovastatin (a pharmaceutical statin), with the same precautions (interactions, myopathy, rare hepatotoxicity); do not combine with statins.
Berberine (500 mg 2-3 times/day): modest LDL reduction and improvement of the glycemic profile, synergistic with low-dose statins.
Citrus bergamot (500-1000 mg/day): modest reduction.
Omega-3 EPA/DHA (2-4 g/day): especially effective for triglycerides (20-30% reduction); modest effect on LDL.
Aged garlic: modest reduction.
Niacin: potent for HDL and triglycerides, but modern trials (AIM-HIGH, HPS2-THRIVE) show no added reduction in events on top of statins; limited use.
In people with: - Established cardiovascular disease. - Diabetes with elevated cardiovascular risk. - LDL > 190 mg/dL (suspected familial hypercholesterolemia). - SCORE cardiovascular risk > 10%.
Statins are first-line treatment because of their robust evidence of reducing cardiovascular and all-cause mortality. Significant adverse effects (clinically important myopathy, hepatotoxicity, new-onset diabetes in predisposed people) are less frequent than popular culture suggests; most patients tolerate statins well.
For moderately elevated cholesterol in people at low risk, nutritional interventions (Mediterranean diet + soluble fiber + phytosterols + nuts) may be sufficient. For markedly elevated cholesterol or significant cardiovascular risk, the combination of nutritional interventions plus statins or a pharmacological equivalent is the best-supported strategy. Red yeast rice is an interesting intermediate alternative with real pharmacological properties from monacolin K, but it should be treated with the same clinical respect as statins.